Intellia files first in-vivo CRISPR therapy with the FDA Phase 3 HAELO cut hereditary-angioedema attacks 87%; rolling BLA for lonvo-z opens the path to the first marketed in-body gene edit 生活如何改变 ·12 takes ·6月24日